Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)



Status:Active, not recruiting
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:10 - Any
Updated:4/21/2016
Start Date:July 2014
End Date:February 2016

Use our guide to learn which trials are right for you!

A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Assess the new film-coated tablet formulation to the currently approved dispersible tablet
formulation with regards to overall safety, Gastrointestinal (GI) tolerability,
palatability, satisfaction and compliance


Inclusion Criteria:

- Male and female patients aged ≥ 10 years

- Patients with transfusion-dependent thalassemia and iron overload, requiring
deferasirox DT at doses of ≥ 30 mg/kg/day as per the investigator's decision OR
Patients with very low, low or intermediate (int) risk myelodysplastic syndrome (MDS)
and iron overload, requiring deferasirox DT at doses of ≥ 20 mg/kg/day as per the
investigator's decision.

- History of transfusion of at least 20 PRBC units and anticipated to be transfused
with at least 8 units of PRBCs annually during the study

- Serum ferritin > 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the
mean value will be used for eligibility criteria).

Exclusion Criteria:

- Creatinine clearance below the contraindication limit in the locally approved
prescribing information. Creatinine clearance will be estimated from serum creatinine
at screening Visit 1 and screening Visit 2 and the mean value will be used for
eligibility criteria.

- Serum creatinine > 1.5 xULN at screening measured at screening Visit 1 and screening
Visit 2 (the mean value will be used for eligibility criteria).

- ALT (SGPT) > 5xULN, unless LIC confirmed as >10 mg Fe/dw within 6 months prior to
screening visit 1.

- Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5
mg/mg in a non-first void urine sample at screening Visit 1 or screening Visit 2.

- Patients with significant impaired gastrointestinal (GI) function or GI disease that
may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases,
uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel
resection).

- Liver disease with severity of Child-Pugh Class B or C
We found this trial at
10
sites
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials